Company Profile

Autus Valve Technologies Inc
Profile last edited on: 2/24/22      CAGE: 8JG43      UEI: PWZ1GQLDP277

Business Identifier: Growth-accommodating synthetic heart valve
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

65 Park Drive Unit 4
Boston, MA 02215
   (617) 390-6468
Location: Single
Congr. District: 07
County: Norfolk

Public Profile

Autus Valve Technologies Inc is structured around development of a medical device designed to prevent the complications of valve prosthesis-patient mismatch. The firm's developed device offers the capability for diameter expansion pre-and post-implantation, via minimally invasive transcatheter balloon dilation, enabling healthcare institutions to improve the overall quality of patient's life and long-term survival, and (potentially) dramatically to reduce incurred health care costs. Bavkground to the projet includes a single-arm, multi-center study to evaluate safety and preliminary effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 2 to 10 years (± 6 months) requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 and 12 months, and annually through 5 years. The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $299,994
Project Title: Biomimetic size-adaptable heart valve for prosthesis-patient mismatch

Key People / Management

  Sophie-Charlotte Hofferberth -- CEO

  Pedro J Del Nido

Company News

There are no news available.